Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma

Clinical Epigenetics

Table 1 Demographic and clinicopathologic characteristics of control and glioma patient cases

Variables	Control (n = 13)	Glioma (n = 15)
Gender
Male	12 (92.3 %)	8 (53.34 %)
Female	1 (7.69 %)	7 (46.67 %)
Age (year)
< 30	2 (15.38 %)	5 (33.34 %)
30–60	7 (53.84 %)	8 (53.34 %)
> 60	4 (30.76 %)	2 (13.34 %)
Smoking (in last 5 year)
Smoker	2 (15.38 %)	2 (13.34 %)
Non-smoker	11 (84.61 %)	13 (86.67 %)
Education level
High school and above	5 (38.46 %)	8 (53.34 %)
Below high school	8 (61.53 %)	7 (46.67 %)
Income level (annual)
< $5000	9 (69.23 %)	11 (73.34 %)
$5000–$10,000	1 (7.68 %)	2 (13.34 %)
> $10,000	3 (23.07 %)	2 (13.34 %)
Biopsy tissue position^a
Frontal	7 (53.84 %)	7 (46.67 %)
Temporal	5 (38.46 %)	4 (26.67 %)
Parietal	0	2 (13.34 %)
Occipital	1 (7.69 %)	3 (20 %)
Others^b	0	2 (13.34 %)
WHO tumor grade
Low-grade glioma (II)	NA	5 (33.34 %)
Malignant glioma (III)	NA	6 (40 %)
Glioblastoma (IV)	NA	4 (26.67 %)
Post-surgery treatment^c
Radiotherapy	NA	1.8 Gy/d (total dose, 50–60 Gy, including 30–36 Gy for brain/spine and 20 Gy for tumor local boost
Chemotherapy	NA	Oral administration of temozolomide (150 mg/m²/d) for first 5 days in a 28-day cycle (total 8 cycles of treatment)

NA not applicable
^aBrain biopsy tissues from three glioma patients were obtained from more than one location. Example includes one of the patients had tumor growth in both frontal and temporal lobe, while two other patients had tumor growth in both parietal and occipital lobe
^bOther positions of biopsy tissue samples include regions such as the fourth ventricle and cerebellum
^cIndividuals that belong to both the cohort of normal and glioma patients were considered based on the criteria that they had no history of other chronic diseases or known long-term exposure to any drugs

ISSN: 1868-7083